The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies

These data reveal that the GEM assay is a useful adjunct in the management of MS patients treated with IFNβ, and that lost bioactivity returns when anti-IFNβ antibody levels diminish.